« Return to News | Study Conduct

Vince & Associates opens neuropsychiatric research center

Thursday, July 14, 2011 12:21 PM

Vince & Associates Clinical Research, a provider of early development clinical trials, has opened the Neuropsychiatric Research Center in Overland Park, Kan.

The research facility will provide study recruitment, medical management and oversight in study volunteers across a range of neuropsychiatric disorders including both acute and chronic schizophrenia.

“While Vince and Associates has been conducting clinical trials in schizophrenia over the past decade, this dedicated unit will allow us to better serve the needs of both study volunteers and our biopharmaceutical clients,” said Dr. Brad Vince, president and medical director.

Debra Kelsh, M.D., a board-certified psychiatrist and an investigator, will serve as medical director of the new Neuropsychiatric Research Center.

Subject recruitment at Vince & Associates is driven by an extensive, proprietary database of more than 40,000 verified patients and healthy normal volunteers. By conducting an in-depth medical history, Vince and Associates helps ensure an accurate estimate of study volunteers available for clinical trials. The company has full-time recruitment staff, a community outreach team and an in-house call center.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.